Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD 1. Read on to learn more about patient populations at risk. May 19, 2025 Elevated lipoprotein(a), also ...

Health disparities in Canada go beyond individual health issues - they underscore deeper societal injustices that undermine our social fabric. These inequities highlight the existence of systemic ...

Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5 Ianalumab Phase II data in immune thrombocytopenia and ...

• Applications are now being accepted, with $500,000 in grants to be awarded to projects focused on improving health equity in Canada Montreal, Quebec, May 14, 2025 – Novartis Pharmaceuticals Canada ...

While the exact reason for this gender imbalance remains unknown, researchers are exploring contributing factors, including hormones, environmental triggers, and antibody levels. 3 Nevertheless, the ...

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From ...

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

The CWP is structured such that a multi-disciplinary health professional team will provide tailored care for patients, aligned with the Primary Care Network (“PCN”) Contract Direct Enhanced Service ...

The company will make a total investment of $23B over the next five years, creating: Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities New ...